Analyses restricted to individuals who initiated ART after entry into the cohort showed similar results. The adjusted change (95% CI) of absolute CD4+ T-cell counts was 26 (12,41; P = 0.0004) for those HCV RNA– and 3.5 (−0.64, 7.7; P = 0.097) for HCV RNA+, with the interaction between HCV RNA status and follow-up time highly significant at P < 0.0001.
Censoring ART exposed patients at the time of first treatment interruption also resulted in similar findings (interaction between HCV RNA status and follow-up time; P = 0.0036). Finally, when restricting to patients with an undetectable viral load throughout follow-up (n = 178), the impact of HCV RNA was attenuated. HCV PCR + patients still had slower CD4 cell recovery (square root CD4, 0.29 vs. 0.51/year) but the interaction term was no longer significant (P = 0.28).
There were only 31 first AIDS defining events in the post-ART period, nondifferentially distributed between HCV RNA– (n = 4, 20%) and HCV RNA+ (n = 27, 15%) individuals. There was no significant difference in the time to AIDS according to HCV PCR status before (hazard ratio 0.62, 95% CI, 0.22–1.80), or after adjustment for baseline CD4 cell and HIV RNA (hazard ratio 0.46, 95% CI, 0.16–1.39).
Understanding the impact of HCV infection on the progression of HIV has important implications for the management of patients with HIV–HCV coinfection. Although it is well established that chronic HCV infection causes premature liver disease in HIV-positive individuals [4,35], the impact of HCV on HIV progression has been thought to be negligible [17,18]. To the best of our knowledge, this is the first study to specifically examine the impact of spontaneous HCV RNA clearance on HIV-disease progression in the setting of HIV–HCV coinfection. We show that after accounting for many clinical and demographic factors that affect HIV progression, spontaneous clearance of HCV infection is independently associated with a better rate of CD4 cell recovery once ART is introduced. There was also a trend to greater CD4 cell decline prior to ART initiation among those chronically infected with HCV when compared with individuals who spontaneously cleared, although this did not reach statistical significance probably due to lack of power.
Our findings were robust with large differences in CD4 cell recovery seen in analyses using both absolute CD4 cell count and CD4%, and in sensitivity analyses restricting to naïve patients initiating ART. The effect of chronic HCV on CD4 cell recovery seen in those initiating ART persisted to a similar degree throughout stable ART, suggesting a continued impact of active HCV replication on immune restoration and potentially on immune function even after years of ART exposure. This effect was not explained by differences in CD4 cell set point, baseline HIV RNA or ART regimen between those chronically infected and spontaneous clearers. The negative association remained after accounting for IDU, updated ART exposure and HIV replication. We could not, however, detect a difference in clinical AIDS events, which were relatively few in number in this cohort of individuals largely well controlled virologically on HIV treatment.
Although data have been conflicting as to the impact of HCV coinfection on immune restoration in patients who commence ART compared with those with HIV infection alone, a metanalysis of eight studies involving 6216 patients concluded that coinfected patients had an increase in CD4 cell count that was on average 33.4 cells/μl (95% CI, 23.5–43.3 cells/μl) lower after at least 1 year of ART . This difference is similar to what we observed between HCV RNA negative and positive persons from the cohort. A recent paper however found no difference in CD4 cell responses after ART initiation among virologically suppressed HCV antibody positive patients according to the presence of HCV viremia  raising possibility that non-adherence or HCV-driven HIV replication may account for poorer CD4 cell outcomes among HCV RNA positive individuals. Although adjusting for HIV RNA in follow-up did not remove the independent effect of HCV RNA in our analyses, when we evaluated CD4 cell responses among those with complete HIV suppression in follow-up, the impact of HCV replication was attenuated. It is, however, difficult to draw conclusions from such post-hoc analyses given the smaller sample size and the biases inherent in selecting individuals based on future HIV response profiles.
The mechanism by which chronic HCV replication may have deleterious effects on CD4 cell count reconstitution cannot be determined from our study. Ongoing T-cell activation related to HCV infection may limit the immunologic responses of patients with sustained viral suppression on ART. For example, for every 5% increase in the proportion of activated CD8+ T-cells, 35 fewer CD4+ T-cells were gained . Significantly elevated CD38 expression in both CD8+ and CD4+ T-cells has been described in HIV–HCV coinfected compared with HCV monoinfected persons and healthy controls, indicating that coinfection is associated with high levels of chronic activation of both T-cell compartments despite effective control of HIV replication by HAART . Interestingly, a reduction in the frequency of activated CD8+ and CD4+ T-cells has been observed after HCV treatment . In fact, we observed higher CD8 cell counts were associated with better CD4 cell responses. However, adjusting for CD8 cell counts did not remove the independent effect of HCV RNA on CD4 cell slope.
Even though we did not observe an impact of poor CD4 cell recovery on AIDS-related outcomes, there may be other important potential consequences to HCV-associated blunted immune recovery. Persistently lower CD4 cell counts while virologically controlled have been associated with higher rates of ART toxicities (e.g. peripheral neuropathy, lipoatrophy, renal dysfunction) . There is also a growing recognition of the importance of immune activation in driving other conditions that are resulting in excess morbidity and mortality in the post-ART era (e.g. liver, cardiovascular and renal disease) [40,41]. Chronic HCV infection may thus handicap the immune system and eradicating HCV through successful HCV treatment may be necessary to allow more robust immune reconstitution and possibly mitigate the effects of chronic HCV on these comorbidities. It would also be of interest to determine in future if differential CD4 cell recovery rates observed might have implications for the risk of these other non-AIDS events in the coinfected population.
A strength of our study is that we compared patients derived from similar populations with similar risk behaviours and lifestyles with and without active HCV RNA replication. Further, we were able to account for IDU and other clinical confounders, as well as for, potential treatment interruptions.
Our primary limitation was insufficient numbers of naïve patients who spontaneously cleared their infection with too short a follow-up time to conclusively determine if chronic HCV infection also impacts CD4 cell count progression prior to ART. Observational studies such as ours are also subject to potential cohort effects. Although we accounted for known factors that might influence outcome measurements, we cannot exclude the possibility of residual confounding. Finally, we were not able to evaluate T-cell function beyond absolute lymphocyte quantification to determine to what degree chronic immune activation or other mechanisms are potentially explanatory.
We found that CD4 cell progression is negatively affected by the presence of ongoing HCV replication in coinfected individuals who are taking ART. Our data support the need to study individuals with chronic replicating HCV separately from those who have cleared their infection when conducting research into HIV–HCV coinfection. Elucidating the mechanisms by which this difference occurs and investigating the impact of HCV treatment on CD4 cell progression should be prioritized. When successful, HCV treatment might have an important role not only in improving HCV related outcomes, but for HIV-related prognosis as well for coinfected persons.
The Canadian co-infection cohort investigators (CTN222) are Drs Jeff Cohen, Windsor Regional Hospital Metroplitan Campus, Windsor, ON; Brian Conway, Downtown IDC, Vancouver, BC; Curtis Cooper, Ottawa General Hospital, Ottawa, ON; Pierre Côté, Clinique du Quartier Latin, Montreal, QC; Joseph Cox, Montreal General Hospital; Montreal, QC; John Gill, Southern Alberta HIV Clinic, Calgary, AB; Mark Tyndall; Native Health Cente, Vancouver, ON; Shariq Haider, McMaster University, Hamilton, ON; Marrianne Harris St Paul's Hospital, Vancouver, BC; David Hasse, Capital District Health Authority, Halifax, NS; Julio Montaner, St Paul's Hospital, Vancouver, BC; Erica Moodie, McGill University, Montreal, QC; Neora Pick Oak Tree Clinic, Vancouver, BC; Annita Rachlis Sunnybrook & Women's College Health Sciences Centre, Toronto, ON; Roger Sandre, HAVEN Program, Sudbury, ON; Danielle Rouleau, Centre Hospitalier de l'Université de Montréal, Montréal, QC; David Wong University Health Network, Toronto, ON; Mark Hull, BC Centre for Excellence in HIV/AIDS, Vancouver, BC; and Sharon Walmsley, Toronto General Hospital, Toronto, ON.
We thank Alex Schnubb, Manon Desmarais, Curtis Sikora, Christine O'Reilly, Brenda Beckthold, Heather Haldane, Laura Puri, Nancy McFarland, Claude Gagne, Elizabeth Knight, Lesley Gallagher, Warmond Chan, Sandra Gordan, Judy Latendre-Paquette, Natalie Jahnke, Viviane Josewski, Evelyn Mann, and Anja McNeil for their assistance with study coordination, participant recruitment and care. We thank Jim Young for statistical advice.
This work was presented in part at the 16th Conference on Retroviruses and Opportunistic Infections (Montreal, February 2009; abstract #836).
This study was funded by the Fonds de recherche en santé du Québec, Réseau SIDA/maladies infectieuses (FRSQ), the Canadian Institutes of Health Research (CIHR MOP-79529) and the CIHR Canadian HIV Trials Network (CTN222). Dr Martin Potter is supported by a CTN Postdoctoral Fellowship award. Dr Marina Klein is supported by a Chercheur-Boursier clinician senior career award from the FRSQ.
M.B.K. is the principal investigator for the study and with M.P. formulated the project, analysed the data and drafted the manuscript. A.O. and H.Y. performed statistical analyses. S.S. managed the study. All of the authors contributed to the acquisition and/or interpretation of the data and revising the manuscript. All of the authors approved the final version of the manuscript for publication.
1. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467–1471.
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492–497.
3. Pol S, Vallet-Pichard A, Fontaine H. Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy. J Viral Hepat 2002; 9:1–8.
4. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, et al
. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14:183–188.
5. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6–9.
6. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558–567.
7. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005; 41:713–720.
8. Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S, et al
. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183:134–137.
9. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, Rios-Villegas MJ, Ruiz-Morales J, Rivero A, et al
. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622–630.
10. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, et al
. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998; 12:381–388.
11. Piroth L, Grappin M, Cuzin L, Mouton Y, Bouchard O, Raffi F, et al
. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hepat 2000; 7:302–308.
12. Carlos Martin J, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 2004; 5:125–131.
13. Dorrucci M, Valdarchi C, Suligoi B, Zaccarelli M, Sinicco A, Giuliani M, et al
. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS 2004; 18:2313–2318.
14. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al
. Coinfection with hepatitis viruses and outcome of initial Antiretroviral regimens in previously naive HIV-Infected subjects. Archives of Internal Medicine 2002; 162:2125–2132.
15. Greub G. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study (vol 356, pg 1800, 2000). Lancet 2001; 357:1536–11536.
16. Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4(+) cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005; 41:906–911.
17. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al
. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992–1002.
18. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199–206.
19. Carmo RA, Guimaraes MDC, Moura AS, Neiva AM, Versiani JB, Lima LV, et al
. The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients. Braz J Infect Dis 2008; 12:173–179.
20. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006; 20:1171–1179.
21. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JMA, et al
. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169–1177.
22. Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, et al
. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002; 76:2817–2826.
23. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, et al
. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 2004; 40:125–132.
24. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534–1543.
25. Korner C, Kramer B, Schulte D, Coenen M, Mauss S, Fatkenheuer G, et al
. Effects of HCV co-infection on apoptosis of CD4(+) T-cells in HIV positive patients. Clin Sci 2009; 116:861–870.
26. Laskus T, Radkowski M, Piasek A, Nowicki M, Horban A, Cianciara J, Rakela J. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000; 181:442–448.
27. Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, et al
. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 2005; 41:667–675.
28. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al.Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe
. J Infect Dis
29. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al
. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37:60–64.
30. Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, et al.Cohort profile: the Canadian HIV-hepatitis C co-infection Cohort Study
. Int J Epidemiol
2009. [Epub ahead of print]
31. Wang YM, Ng WC, Lo SK. Suppression of hepatitis C virus by hepatitis B virus in coinfected patients at the National University Hospital of Singapore. J Gastroenterol 1999; 34:481–485.
32. Koike K, Yasuda K, Yotsuyanagi H, Moriya K, Hino K, Kurokawa K, Iino S. Dominant replication of either virus in dual infection with hepatitis viruses B and C. J Med Virol 1995; 45:236–239.
33. Bacchetti P, Tien PC, Seaberg EC, O'Brien TR, Augenbraun MH, Kral AH, et al
. Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis 2007; 7:145.
34. Diggle PJ, Heagerty P, Liang K-Y, Zeger SL. Analysis of Longitudinal Data
. 2nd ed. New York: Oxford University Press; 2002.
35. Macias J, Melguizo I, Fernandez-Rivera FJ, Garcia-Garcia A, Mira JA, Ramos AJ, et al
. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002; 21:775–781.
36. Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, et al
. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009; 50:457–463.
37. Gonzalez VD, Falconer K, Blom KG, Reichard O, Morn B, Laursen AL, et al
. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 83:11407–11411.
38. Laskus T, Radkowski M, Jablonska J, Kibler K, Wilkinson J, Adair D, Rakela J. Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood 2004; 103:3854–3859.
39. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Moorman AC, Wood KC, et al
. Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008; 47:27–35.
40. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al
. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993–2003.
41. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al
. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283–2296.